announces that the U.S. Food and Drug Administration has accepted the Biologics License Application or BLA for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx ...
MELBOURNE, Australia and INDIANAPOLIS, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug ...
for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA3 date of 27 August 2025 ...
No description, website, or topics provided.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback